{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:41:41Z","timestamp":1792399301370,"version":"4.4.0"},"reference-count":45,"publisher":"American Association for the Advancement of Science (AAAS)","funder":[{"name":"National Key R&D Program of China","award":["2023YFC3606302"],"award-info":[{"award-number":["2023YFC3606302"]}]}],"content-domain":{"domain":["spj.science.org"],"crossmark-restriction":true},"short-container-title":["Health Data Sci"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Limited evidence exists regarding the association of cardiovascular health (CVH) with metabolic dysfunction-associated steatotic liver disease (MASLD) in Chinese adults, and the influence of genetic risk on this association remains unknown. This study aimed to investigate these associations and discern potential variations based on genetic risk.\n                    <jats:bold>Methods:<\/jats:bold>\n                    This cross-sectional study included 17,077 participants from the third resurvey of the China Kadoorie Biobank. CVH was evaluated by Life\u2019s Essential 8 (LE8), with the overall score (0 to 100) calculated as the unweighted average of its 8 component scores and categorized as low (0 to 49), moderate (50 to 79), or high (80 to 100). Polygenic risk score (PRS) for MASLD was generated by meta-analytic approach and large genome-wide association data of liver steatosis and related traits. Genetic risk for MASLD was categorized into low, intermediate, and high based on quintile of metaPRS. The multivariable logistic regression model was used to evaluate the associations of CVH with MASLD and advanced fibrosis in MASLD, subsequently stratified by metaPRS.\n                    <jats:bold>Results:<\/jats:bold>\n                    High CVH was associated with over 90% lower risk of MASLD and advanced fibrosis in MASLD, with odds ratios of 0.07 (0.06 to 0.08) and 0.04 (0.02 to 0.05) compared to low CVH, respectively. Interactions of metaPRS were observed for the impacts of LE8 on both prevalent MASLD and advanced fibrosis in MASLD (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    value for interaction &lt;0.02 and &lt;0.001, respectively), with stronger protective associations among individuals with higher genetic risk. Similar findings were observed when we tentatively expanded LE8 to Life\u2019s Crucial 9 (LC9), incorporating the psychological health component.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    In Chinese adults, adhering to a high CVH was associated with lower odds of prevalent MASLD and advanced fibrosis in MASLD, particularly among individuals at high genetic risk.\n                  <\/jats:p>","DOI":"10.34133\/hds.0416","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:05:03Z","timestamp":1776769503000},"update-policy":"https:\/\/doi.org\/10.34133\/aaas_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Life\u2019s Essential 8, Genetic Susceptibility, and Metabolic Dysfunction-Associated Steatotic Liver Disease in Chinese Adults"],"prefix":"10.34133","volume":"6","author":[{"given":"Shuyao","family":"Song","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, \rPeking University, Beijing 100191, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, \rPeking University, Beijing 100191, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, \rPeking University, Beijing 100191, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, \rPeking University, Beijing 100191, China."},{"name":"Peking University Center for Public Health and Epidemic Preparedness and Response","place":["China"]},{"name":"Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China."},{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling","place":["China"]},{"name":"Peking University","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canqing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, \rPeking University, Beijing 100191, China."},{"name":"Peking University Center for Public Health and Epidemic Preparedness and Response","place":["China"]},{"name":"Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianjianyi","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, \rPeking University, Beijing 100191, China."},{"name":"Peking University Center for Public Health and Epidemic Preparedness and Response","place":["China"]},{"name":"Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, \rPeking University, Beijing 100191, China."},{"name":"Peking University Center for Public Health and Epidemic Preparedness and Response","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, \rPeking University, Beijing 100191, China."},{"name":"Peking University Center for Public Health and Epidemic Preparedness and Response","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yang","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, \rUniversity of Oxford, Oxford, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, \rUniversity of Oxford, Oxford, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaidong","family":"Du","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, \rUniversity of Oxford, Oxford, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Bragg","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, \rUniversity of Oxford, Oxford, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iona","family":"Millwood","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, \rUniversity of Oxford, Oxford, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Walters","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, \rUniversity of Oxford, Oxford, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Li","sequence":"additional","affiliation":[{"name":"Jili Community Health Service","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, \rUniversity of Oxford, Oxford, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Barnard","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, \rUniversity of Oxford, Oxford, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junshi","family":"Chen","sequence":"additional","affiliation":[{"name":"China National Center for Food Safety Risk Assessment","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengming","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, \rUniversity of Oxford, Oxford, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, \rPeking University, Beijing 100191, China."},{"name":"Peking University Center for Public Health and Epidemic Preparedness and Response","place":["China"]},{"name":"Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjie","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, \rPeking University, Beijing 100191, China."},{"name":"Peking University Center for Public Health and Epidemic Preparedness and Response","place":["China"]},{"name":"Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"China Kadoorie Biobank Collaborative Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"issue":"6","key":"e_1_3_5_2_2","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u20131556.","journal-title":"J Hepatol"},{"issue":"4","key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/hep.30702","article-title":"Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis","volume":"70","author":"Zhou F","year":"2019","unstructured":"Zhou F, Zhou J, Wang W, Zhang X-J, Ji Y-X, Zhang P, She Z-G, Zhu L, Cai J, Li H. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis. Hepatology. 2019;70(4):1119\u20131133.","journal-title":"Hepatology"},{"issue":"4","key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1053\/j.gastro.2023.05.053","article-title":"Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: A nationwide study with 5.7 million adults in China","volume":"165","author":"Man S","year":"2023","unstructured":"Man S, Deng Y, Ma Y, Fu J, Bao H, Yu C, Lv J, Liu H, Wang B, Li L. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: A nationwide study with 5.7 million adults in China. Gastroenterology. 2023;165(4):1025\u20131040.","journal-title":"Gastroenterology"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00165-0"},{"issue":"10290","key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell EE","year":"2021","unstructured":"Powell EE, Wong VWS, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212\u20132224.","journal-title":"Lancet"},{"issue":"5","key":"e_1_3_5_7_2","first-page":"e18","article-title":"Life\u2019s Essential 8: Updating and enhancing the American Heart Association\u2019s construct of cardiovascular health: A presidential advisory from the American Heart Association","volume":"146","author":"Lloyd-Jones DM","year":"2022","unstructured":"Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LC, Foraker RE, Grandner MA, Lavretsky H, Perak AM, Sharma G, et al. Life\u2019s Essential 8: Updating and enhancing the American Heart Association\u2019s construct of cardiovascular health: A presidential advisory from the American Heart Association. Circulation. 2022;146(5):e18\u2013e43.","journal-title":"Circulation"},{"issue":"9","key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1161\/CIRCULATIONAHA.123.066132","article-title":"Strengthening the pillars of cardiovascular health: Psychological health is a crucial component","volume":"149","author":"Gaffey AE","year":"2024","unstructured":"Gaffey AE, Rollman BL, Burg MM. Strengthening the pillars of cardiovascular health: Psychological health is a crucial component. Circulation. 2024;149(9):641\u2013643.","journal-title":"Circulation"},{"issue":"7","key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/eurjpc\/zwad033","article-title":"\u201cLife\u2019s Essential 8\u201d cardiovascular health with premature cardiovascular disease and all-cause mortality in young adults: The Kailuan prospective cohort study","volume":"30","author":"Xing A","year":"2023","unstructured":"Xing A, Tian X, Wang Y, Chen S, Xu Q, Xia X, Zhang Y, Zhang X, Wang A, Wu S. \u201cLife\u2019s Essential 8\u201d cardiovascular health with premature cardiovascular disease and all-cause mortality in young adults: The Kailuan prospective cohort study. Eur J Prev Cardiol. 2023;30(7):593\u2013600.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.amepre.2023.01.009","article-title":"Life\u2019s Essential 8 and 10-year and lifetime risk of atherosclerotic cardiovascular disease in China","volume":"64","author":"Jin C","year":"2023","unstructured":"Jin C, Li J, Liu F, Li X, Hui Y, Chen S, Li F, Wang G, Liang F, Lu X, et al. Life\u2019s Essential 8 and 10-year and lifetime risk of atherosclerotic cardiovascular disease in China. Am J Prev Med. 2023;64(6):927\u2013935.","journal-title":"Am J Prev Med"},{"issue":"2","key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.numecd.2023.09.018","article-title":"Association between updated cardiovascular health construct and risks of non-alcoholic fatty liver disease","volume":"34","author":"Huang J","year":"2024","unstructured":"Huang J, Xin Z, Cao Q, He R, Hou T, Ding Y, Lu J, Wang T, Zhao Z, Xu Y, et al. Association between updated cardiovascular health construct and risks of non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2024;34(2):317\u2013325.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/MEG.0000000000001069","article-title":"Association of the ideal cardiovascular behaviors and factors with the incidence of nonalcoholic fatty liver disease: A prospective study","volume":"30","author":"Zhu S","year":"2018","unstructured":"Zhu S, Shi J, Ji C, Yang G, Xing J, Zhu F, Lin L, Xing A, Huang Z, Zhu C, et al. Association of the ideal cardiovascular behaviors and factors with the incidence of nonalcoholic fatty liver disease: A prospective study. Eur J Gastroenterol Hepatol. 2018;30(5):578\u2013582.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.09.013","article-title":"Genetic and non-genetic drivers of histological progression and regression in MASLD","volume":"84","author":"Vilar-Gomez E","year":"2026","unstructured":"Vilar-Gomez E, Yates KP, Kleiner DE, Behling C, Cummings OW, Wilson LA, Liang T, Jarasvaraparn C, Loomba R, Schwimmer JB, et al. Genetic and non-genetic drivers of histological progression and regression in MASLD. J Hepatol. 2026;84(3):502\u2013516.","journal-title":"J Hepatol"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01497-6"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01078-z"},{"issue":"6","key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/apt.16772","article-title":"NAFLD-related gene polymorphisms and all-cause and cause-specific mortality in an Asian population: The Shanghai Changfeng Study","volume":"55","author":"Xia M","year":"2022","unstructured":"Xia M, Ma S, Huang Q, Zeng H, Ge J, Xu W, Wu Q, Wu L, Li X, Ma H, et al. NAFLD-related gene polymorphisms and all-cause and cause-specific mortality in an Asian population: The Shanghai Changfeng Study. Aliment Pharmacol Ther. 2022;55(6):705\u2013721.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1038\/s41467-019-11112-0","article-title":"Analysis of polygenic risk score usage and performance in diverse human populations","volume":"10","author":"Duncan L","year":"2019","unstructured":"Duncan L, Shen H, Gelaye B, Meijsen J, Ressler K, Feldman M, Peterson R, Domingue B. Analysis of polygenic risk score usage and performance in diverse human populations. Nat Commun. 2019;10(1):3328.","journal-title":"Nat Commun"},{"issue":"6","key":"e_1_3_5_18_2","first-page":"e619","article-title":"Development and validation of a polygenic risk score for stroke in the Chinese population","volume":"97","author":"Lu X","year":"2021","unstructured":"Lu X, Niu X, Shen C, Liu F, Liu Z, Huang K, Wang L, Li J, Hu D, Zhao Y, et al. Development and validation of a polygenic risk score for stroke in the Chinese population. Neurology. 2021;97(6):e619\u2013e628.","journal-title":"Neurology"},{"issue":"18","key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/eurheartj\/ehac093","article-title":"A polygenic risk score improves risk stratification of coronary artery disease: A large-scale prospective Chinese cohort study","volume":"43","author":"Lu X","year":"2022","unstructured":"Lu X, Liu Z, Cui Q, Liu F, Li J, Niu X, Shen C, Hu D, Huang K, Chen J, et al. A polygenic risk score improves risk stratification of coronary artery disease: A large-scale prospective Chinese cohort study. Eur Heart J. 2022;43(18):1702\u20131711.","journal-title":"Eur Heart J"},{"issue":"18","key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/eurheartj\/ehab923","article-title":"Polygenic risk score: A tool ready for clinical use?","volume":"43","author":"Kavousi M","year":"2022","unstructured":"Kavousi M, Schunkert H. Polygenic risk score: A tool ready for clinical use? Eur Heart J. 2022;43(18):1712\u20131714.","journal-title":"Eur Heart J"},{"issue":"6","key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/ije\/dyr120","article-title":"China Kadoorie Biobank of 0.5 million people: Survey methods, baseline characteristics and long-term follow-up","volume":"40","author":"Chen Z","year":"2011","unstructured":"Chen Z, Chen J, Collins R, Guo Y, Peto R, Wu F, Li L, on behalf of the China Kadoorie Biobank (CKB) Collaborative Group. China Kadoorie Biobank of 0.5 million people: Survey methods, baseline characteristics and long-term follow-up. Int J Epidemiol. 2011;40(6):1652\u20131666.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"e_1_3_5_22_2","first-page":"1","article-title":"Progress and achievements of large natural population cohort demonstration study","volume":"44","author":"Guo Y","year":"2023","unstructured":"Guo Y, Yu C, Lyu J, et al. Progress and achievements of large natural population cohort demonstration study. Chin J Epidemiol. 2023;44(1):1\u20136.","journal-title":"Chin J Epidemiol"},{"issue":"11","key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41588-022-01199-5","article-title":"Multiomics study of nonalcoholic fatty liver disease","volume":"54","author":"Sveinbjornsson G","year":"2022","unstructured":"Sveinbjornsson G, Ulfarsson MO, Thorolfsdottir RB, Jonsson BA, Einarsson E, Gunnlaugsson G, Rognvaldsson S, Arnar DO, Baldvinsson M, Bjarnason RG, et al. Multiomics study of nonalcoholic fatty liver disease. Nat Genet. 2022;54(11):1652\u20131663.","journal-title":"Nat Genet"},{"issue":"11","key":"e_1_3_5_24_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2021.100437","article-title":"Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease","volume":"2","author":"Ghodsian N","year":"2021","unstructured":"Ghodsian N, Abner E, Emdin CA, Gobeil \u00c9, Taba N, Haas ME, Perrot N, Manikpurage HD, Gagnon \u00c9, Bourgault J, et al. Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. Cell Rep Med. 2021;2(11): Article 100437.","journal-title":"Cell Rep Med"},{"issue":"3","key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort\u2606","volume":"73","author":"Anstee QM","year":"2020","unstructured":"Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, Burt AD, Bedossa P, Palmer J, Liu YL, et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort\u2606. J Hepatol. 2020;73(3):505\u2013515.","journal-title":"J Hepatol"},{"issue":"7","key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cgh.2022.01.045","article-title":"Mendelian randomization analysis reveals no causal relationship between nonalcoholic fatty liver disease and severe COVID-19","volume":"20","author":"Li J","year":"2022","unstructured":"Li J, Tian A, Zhu H, Chen L, Wen J, Liu W, Chen P. Mendelian randomization analysis reveals no causal relationship between nonalcoholic fatty liver disease and severe COVID-19. Clin Gastroenterol Hepatol. 2022;20(7):1553\u20131560.e78.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1038\/s41467-019-13848-1","article-title":"Genomic risk score offers predictive performance comparable to clinical risk factors for ischaemic stroke","volume":"10","author":"Abraham G","year":"2019","unstructured":"Abraham G, Malik R, Yonova-Doing E, Salim A, Wang T, Danesh J, Butterworth AS, Howson JMM, Inouye M, Dichgans M. Genomic risk score offers predictive performance comparable to clinical risk factors for ischaemic stroke. Nat Commun. 2019;10(1):5819.","journal-title":"Nat Commun"},{"issue":"4","key":"e_1_3_5_28_2","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000323","article-title":"Diagnostic performance of FibroTouch ultrasound attenuation parameter and liver stiffness measurement in assessing hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"12","author":"Qu Y","year":"2021","unstructured":"Qu Y, Song YY, Chen CW, Fu QC, Shi JP, Xu Y, Xie Q, Yang YF, Zhou YJ, Li LP, et al. Diagnostic performance of FibroTouch ultrasound attenuation parameter and liver stiffness measurement in assessing hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Clin Transl Gastroenterol. 2021;12(4): Article e00323.","journal-title":"Clin Transl Gastroenterol"},{"issue":"9","key":"e_1_3_5_29_2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/1751-2980.12924","article-title":"Multicenter prospective study to validate a new transient elastography device for staging liver fibrosis in patients with chronic hepatitis B","volume":"21","author":"Duan WJ","year":"2020","unstructured":"Duan WJ, Wang XZ, Ma AL, Shang J, Nan YM, Gao ZL, Tang H, Fu QC, Xie Q, Mao Q, et al. Multicenter prospective study to validate a new transient elastography device for staging liver fibrosis in patients with chronic hepatitis B. J Dig Dis. 2020;21(9):519\u2013525.","journal-title":"J Dig Dis"},{"issue":"3","key":"e_1_3_5_30_2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/ije\/dyi181","article-title":"Validation of verbal autopsy procedures for adult deaths in China","volume":"35","author":"Yang G","year":"2006","unstructured":"Yang G, Rao C, Ma J, Wang L, Wan X, Dubrovsky G, Lopez AD. Validation of verbal autopsy procedures for adult deaths in China. Int J Epidemiol. 2006;35(3):741\u2013748.","journal-title":"Int J Epidemiol"},{"issue":"2","key":"e_1_3_5_31_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults: A review","volume":"335","author":"Tilg H","year":"2026","unstructured":"Tilg H, Petta S, Stefan N, Targher G. Metabolic dysfunction-associated steatotic liver disease in adults: A review. JAMA. 2026;335(2):163\u2013174.","journal-title":"JAMA"},{"issue":"12","key":"e_1_3_5_32_2","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCRESAHA.123.321998","article-title":"Life course cardiovascular health: Risk factors, outcomes, and interventions","volume":"132","author":"Pedamallu H","year":"2023","unstructured":"Pedamallu H, Zmora R, Perak AM, Allen NB. Life course cardiovascular health: Risk factors, outcomes, and interventions. Circ Res. 2023;132(12):1570\u20131583.","journal-title":"Circ Res"},{"issue":"1","key":"e_1_3_5_33_2","doi-asserted-by":"crossref","first-page":"23999","DOI":"10.1038\/s41598-024-74791-w","article-title":"The correlation between life\u2019s essential 8 and cardiovascular disease and mortality in individuals with nonalcoholic fatty liver disease: A cross-sectional study","volume":"14","author":"Sun M","year":"2024","unstructured":"Sun M, Qiu Y, Zhang L, Chen G. The correlation between life\u2019s essential 8 and cardiovascular disease and mortality in individuals with nonalcoholic fatty liver disease: A cross-sectional study. Sci Rep. 2024;14(1):23999.","journal-title":"Sci Rep"},{"issue":"8","key":"e_1_3_5_34_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.xgen.2023.100361","article-title":"Genotyping and population characteristics of the China Kadoorie Biobank","volume":"3","author":"Walters RG","year":"2023","unstructured":"Walters RG, Millwood IY, Lin K, Schmidt Valle D, McDonnell P, Hacker A, Avery D, Edris A, Fry H, Cai N, et al. Genotyping and population characteristics of the China Kadoorie Biobank. Cell Genomics. 2023;3(8): Article 100361.","journal-title":"Cell Genomics"},{"issue":"11","key":"e_1_3_5_35_2","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1161\/CIRCULATIONAHA.122.060911","article-title":"Status of cardiovascular health in US adults and children using the American Heart Association\u2019s new \u201cLife\u2019s Essential 8\u201d metrics: Prevalence estimates from the National Health and Nutrition Examination Survey (NHANES), 2013 through 2018","volume":"146","author":"Lloyd-Jones DM","year":"2022","unstructured":"Lloyd-Jones DM, Ning H, Labarthe D, Brewer LP, Sharma G, Rosamond W, Foraker RE, Black T, Grandner MA, Allen NB, et al. Status of cardiovascular health in US adults and children using the American Heart Association\u2019s new \u201cLife\u2019s Essential 8\u201d metrics: Prevalence estimates from the National Health and Nutrition Examination Survey (NHANES), 2013 through 2018. Circulation. 2022;146(11):822\u2013835.","journal-title":"Circulation"},{"issue":"2","key":"e_1_3_5_36_2","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.jhep.2022.10.014","article-title":"Life\u2019s Essential 8 and MAFLD in the United States","volume":"78","author":"Wang X","year":"2023","unstructured":"Wang X, Wang A, Zhang R, Cheng S, Pang Y. Life\u2019s Essential 8 and MAFLD in the United States. J Hepatol. 2023;78(2):e61\u2013e63.","journal-title":"J Hepatol"},{"issue":"1","key":"e_1_3_5_37_2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/hep4.1614","article-title":"Adherence to ideal cardiovascular health metrics is associated with reduced odds of hepatic steatosis","volume":"5","author":"Decoste LR","year":"2020","unstructured":"Decoste LR, Wang N, Palmisano JN, Mendez J, Hoffmann U, Benjamin EJ, Long MT. Adherence to ideal cardiovascular health metrics is associated with reduced odds of hepatic steatosis. Hepatol Commun. 2020;5(1):74\u201382.","journal-title":"Hepatol Commun"},{"issue":"7","key":"e_1_3_5_38_2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10654-022-00868-3","article-title":"Lifestyle and metabolic factors for nonalcoholic fatty liver disease: Mendelian randomization study","volume":"37","author":"Yuan S","year":"2022","unstructured":"Yuan S, Chen J, Li X, Fan R, Arsenault B, Gill D, Giovannucci EL, Zheng JS, Larsson SC. Lifestyle and metabolic factors for nonalcoholic fatty liver disease: Mendelian randomization study. Eur J Epidemiol. 2022;37(7):723\u2013733.","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"e_1_3_5_39_2","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.31238","article-title":"Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population","volume":"72","author":"Gellert-Kristensen H","year":"2020","unstructured":"Gellert-Kristensen H, Richardson TG, Davey Smith G, Nordestgaard BG, Tybjaerg-Hansen A, Stender S. Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. Hepatology. 2020;72(3):845\u2013856.","journal-title":"Hepatology"},{"issue":"6","key":"e_1_3_5_40_2","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"59","author":"European Association for the Study of the Liver (EASL)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59(6):1121\u20131140.","journal-title":"Diabetologia"},{"key":"e_1_3_5_41_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155643","article-title":"A healthy lifestyle, Life\u2019s Essential 8 scores and new-onset severe NAFLD: A prospective analysis in UK Biobank","volume":"146","author":"He P","year":"2023","unstructured":"He P, Zhang Y, Ye Z, Li H, Liu M, Zhou C, Yang S, Gan X, Zhang Y, Qin X. A healthy lifestyle, Life\u2019s Essential 8 scores and new-onset severe NAFLD: A prospective analysis in UK Biobank. Metabolism. 2023;146: Article 155643.","journal-title":"Metabolism"},{"issue":"5","key":"e_1_3_5_42_2","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD)","volume":"28","author":"Cusi K","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528\u2013562.","journal-title":"Endocr Pract"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323"},{"issue":"9","key":"e_1_3_5_44_2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.dld.2019.02.009","article-title":"Comparison of FibroTouch and FibroScan for staging fibrosis in chronic liver disease: Single-center prospective study","volume":"51","author":"Xu Y","year":"2019","unstructured":"Xu Y, Liu Y, Cao Z, Wang L, Li Z, Sheng Z, Cai W, Wang H, Bao S, Xie Q. Comparison of FibroTouch and FibroScan for staging fibrosis in chronic liver disease: Single-center prospective study. Dig Liver Dis. 2019;51(9):1323\u20131329.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"e_1_3_5_45_2","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s10620-021-07049-4","article-title":"Diagnostic value of FibroTouch and non-invasive fibrosis indexes in hepatic fibrosis with different aetiologies","volume":"67","author":"Peng X","year":"2022","unstructured":"Peng X, Tian A, Li J, Mao Y, Jiang N, Li T, Mao X. Diagnostic value of FibroTouch and non-invasive fibrosis indexes in hepatic fibrosis with different aetiologies. Dig Dis Sci. 2022;67(6):2627\u20132636.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"e_1_3_5_46_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0250300","article-title":"Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease","volume":"16","author":"Ng YZ","year":"2021","unstructured":"Ng YZ, Lai LL, Wong SW, Mohamad SY, Chuah KH, Chan WK. Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease. PLOS ONE. 2021;16(5): Article e0250300.","journal-title":"PLOS ONE"}],"container-title":["Health Data Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.34133\/hds.0416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:00:46Z","timestamp":1792396846000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.34133\/hds.0416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":45,"alternative-id":["10.34133\/hds.0416"],"URL":"https:\/\/doi.org\/10.34133\/hds.0416","relation":{},"ISSN":["2765-8783"],"issn-type":[{"value":"2765-8783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"assertion":[{"value":"2025-12-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"0416"}}